Colorectal cancer
Conditions
Interventions
Corhot 1: second-line cross to third-line:None
Corhot 2: third-line cross to fourth-line:None
Sponsors
Xiantao First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: To be enrolled in this study, patients must meet all of the following criteria: Corhot 1: second-line cross to third-line 1. Age =18 years and =75 years; 2. No gender limitation; 3. Patients with metastatic colorectal cancer confirmed by histopathology had previously received first-line treatment with bevacizumab combined with standard chemotherapy, and second-line treatment with fruquintinib combined with standard chemotherapy. After progression , fruquintinib combined with PD-1 inhibitors and chemotherapy had been received as third-line treatment. 4. Fruquintinib was received at least one cycle after crossing to the third-line. 5. Imaging assessment of tumors was done at least once after crossing to the third-line. 6. ECOG PS 0-1 before crossing to the third-line. Corhot 2: third-line cross to fourth-line 1. Age =18 years and =75 years; 2. No gender limitation; 3. Patients with metastatic colorectal cancer confirmed by histopathology had previously received two lines system therapy which included fluorouracil, oxaliplatin, irinotecan, anti-VEGF, anti-EGFR (RAS and BRAF wild type) (treatment with anti-VEGF-TKI is not allowed), and had received fruquintinib-based regimens as third-line treatment, and had continued fruquintinib-based regimens as fourth-line treatment after progression. 4. Fruquintinib was received at least one cycle after crossing to the fourth-line. 5. Imaging assessment of tumors was done at least once after crossing to the fourth-line. 6. ECOG PS 0-1 before crossing to the fourth-line.
Exclusion criteria
Exclusion criteria: Patients will not be admitted to the study if they meet any of the following criteria: Corhot 1: second-line cross to third-line 1. Patients with contraindications to study drugs (fruquintinib, PD-1 inhibitors, chemotherapy drugs); 2. Allergic to the investigational drug or any of its adjuncts; 3. There are other non-investigational drugs during second-line and third-line treatment 4. Pregnant or lactating female subjects; 5. Patients with a large number of pleural effusion or ascites requiring drainage; 6. No tumor efficacy evaluation was performed after treatment with fruquintinib 7. Patients whose follow-up information was insufficient for analysis determined by the investigator (e.g., No more visits to the hospital for treatment or evaluation after initial treatment) Corhot 2: third-line cross to fourth-line 1. Patients with contraindications to study drugs (fruquintinib, PD-1 inhibitors, chemotherapy drugs); 2. Allergic to the investigational drug or any of its adjuncts; 3. There are other non-investigational drugs during third-line and fourth-line treatment 4. Pregnant or lactating female subjects; 5. Patients with a large number of pleural effusion or ascites requiring drainage; 6. No tumor efficacy evaluation was performed after treatment with fruquintinib 7. Patients whose follow-up information was insufficient for analysis determined by the investigator (e.g., No more visits to the hospital for treatment or evaluation after initial treatment)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival(PFS);Overall survival(OS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate(ORR);Disease control rate(DCR); | — |
Countries
China
Contacts
Public ContactLiPing Li
Xiantao First People's Hospital
Outcome results
None listed